Curaleaf Holdings, Inc.
Curaleaf Holdings, Inc. Fundamental Analysis
Curaleaf Holdings, Inc. (CURA.TO) shows weak financial fundamentals with a PE ratio of -9.67, profit margin of -19.01%, and ROE of -29.97%. The company generates $1.3B in annual revenue with weak year-over-year growth of -6.78%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -36.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CURA.TO's fundamental strength across five key dimensions:
Efficiency Score
WeakCURA.TO struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCURA.TO trades at attractive valuation levels.
Growth Score
ModerateCURA.TO shows steady but slowing expansion.
Financial Health Score
ModerateCURA.TO shows balanced financial health with some risks.
Profitability Score
WeakCURA.TO struggles to sustain strong margins.
Key Financial Metrics
Is CURA.TO Expensive or Cheap?
P/E Ratio
CURA.TO trades at -9.67 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CURA.TO's PEG of -2.18 indicates potential undervaluation.
Price to Book
The market values Curaleaf Holdings, Inc. at 3.12 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 6.69 times EBITDA. This is generally considered low.
How Well Does CURA.TO Make Money?
Net Profit Margin
For every $100 in sales, Curaleaf Holdings, Inc. keeps $-19.01 as profit after all expenses.
Operating Margin
Core operations generate 1.41 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-29.97 in profit for every $100 of shareholder equity.
ROA
Curaleaf Holdings, Inc. generates $-8.59 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Curaleaf Holdings, Inc. produces operating cash flow of $140.21M, showing steady but balanced cash generation.
Free Cash Flow
Curaleaf Holdings, Inc. produces free cash flow of $75.29M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.10 in free cash annually.
FCF Yield
CURA.TO converts 3.11% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-9.67
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-2.18
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.12
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.86
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.37
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.52
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.30
vs 25 benchmark
ROA
Return on assets percentage
-0.09
vs 25 benchmark
ROCE
Return on capital employed
0.007
vs 25 benchmark
How CURA.TO Stacks Against Its Sector Peers
| Metric | CURA.TO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -9.67 | 29.04 | Better (Cheaper) |
| ROE | -29.97% | 712.00% | Weak |
| Net Margin | -19.01% | -44581.00% (disorted) | Weak |
| Debt/Equity | 1.37 | 0.34 | Weak (High Leverage) |
| Current Ratio | 1.52 | 4.53 | Neutral |
| ROA | -8.59% | -18069.00% (disorted) | Weak |
CURA.TO outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Curaleaf Holdings, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
253.20%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-105.90%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
365.09%
Industry Style: Defensive, Growth, Innovation
High Growth